Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • CDK
    (11)
  • PROTACs
    (2)
  • Apoptosis
    (1)
  • EGFR
    (1)
  • HDAC
    (1)
  • Others
    (17)
Filter
Search Result
Results for "

CDK4/6-IN-6

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    38
    TargetMol | Inhibitors_Agonists
  • Compound Libraries
    1
    TargetMol | Compound_Libraries
  • PROTAC Products
    5
    TargetMol | PROTAC
  • Recombinant Protein
    2
    TargetMol | Recombinant_Protein
CDK4/6-IN-2
T107361800506-48-2
CDK4 6-IN-2 is a potent inhibitor of CDK4 and CDK6 [IC50s: 2.7 and 16 nM].
  • Inquiry Price
Size
QTY
CDK4/6-IN-3
T107372366237-37-6
CDK4 6-IN-3, a brain-penetrant CDK4 CDK6 inhibitor (Kis: <0.3 nM and 2.2 nM), is used for the treatment of glioblastoma and inhibits CDK1 with a Ki of 110 nM.
  • Inquiry Price
3-6 months
Size
QTY
CDK4/6-IN-23
T204550
CDK4 6-IN-23 (Compound 42) is a potent and selective inhibitor of CDK4 6, displaying an IC50 of 11 nM for CDK6. This compound significantly activates immune cells and enhances IL-3 production. In mice undergoing 5-FU chemotherapy, CDK4 6-IN-23 demonstrates dual bone marrow protection and immunomodulatory effects.
  • Inquiry Price
Size
QTY
CDK4/6/HDAC-IN-1
T204833
CDK4 6 HDAC-IN-1 (Compound N14) is a dual-target inhibitor of CDK4 6 and HDAC, with IC50 values of 7.23 nM for CDK4, 13.20 nM for CDK6, 55.66 nM for HDAC1, and 48.38 nM for HDAC6. It induces apoptosis and G0 G1 phase arrest through the HDAC-p21-CDK signaling pathway and can inhibit hepatocellular carcinoma.
  • Inquiry Price
Size
QTY
CDK4/6-IN-24
T2056282662813-96-7
CDK4 6-IN-24 (Compound A) is an inhibitor of CDK4 6 with broad-spectrum antitumor activity. It can effectively inhibit various cancer cells, exhibiting an IC50 in the submicromolar range.
  • Inquiry Price
10-14 weeks
Size
QTY
CDK4/6-IN-5
CDK4 6-IN-5
T399562380321-50-4
CDK4 6-IN-5 is a highly effective inhibitor of CDK4 and CDK6, with Ki values of 0.2 nM for CDK4 Cyclin D1 and 4.4 nM for CDK6 Cyclin D3 (WO2019207463A1, example A93).
  • Inquiry Price
Size
QTY
cdk4/6-in-12
T603282445205-24-1
CDK4 6-IN-12 is a potent cyclin-dependent kinase 4 6 (CDK4 6) inhibitor with enzymatic inhibitory activity against CDK4 and CDK6, having IC50 values of 592.3 nM and 3090 nM, respectively. CDK4 6-IN-12 can be used in cancer research[1].
  • Inquiry Price
6-8 weeks
Size
QTY
cdk4/6-in-7
T617382649120-20-5
CDK4 6-IN-7, a highly potent and selective orally active inhibitor of CDK4 6, demonstrates impressive inhibition activity with IC50 values of 1.58 nM and 4.09 nM respectively. This compound is particularly valuable for breast cancer research [1].
  • Inquiry Price
6-8 weeks
Size
QTY
cdk4/6-in-8
T618922649120-22-7
CDK4 6-IN-8 (Compound 7p) is a selective inhibitor of CDK4 with an IC50 of 5.01 nM and CDK6 with an IC50 of 3.97 nM.
  • Inquiry Price
6-8 weeks
Size
QTY
cdk4/6-in-9
T621922688098-02-2
CDK4 6-IN-9 (compound 10) is a selective inhibitor of CDK4 6, demonstrating activity on CDK6 cyclin D1 (IC50: 905 nM), and holds potential research value in multiple myeloma (MM).
  • Inquiry Price
6-8 weeks
Size
QTY
cdk4/6-in-10
T64244
CDK4 6-IN-10 is a selective, potent, orally active inhibitor of CDK4 (IC50: 22 nM) and CDK6 (IC50: 10 nM) with antitumour effects, showing potential for studies in multiple myeloma (MM).
  • Inquiry Price
10-14 weeks
Size
QTY
cdk4/6-in-15
T729282078047-99-9
CDK4 6-IN-15, an orally active and selective inhibitor of CDK4 6, effectively halts the growth of cancer cells by arresting the cell cycle at the G1 phase and inhibiting the phosphorylation of the retinoblastoma tumor suppressor protein (Rb) at S780, as well as suppressing E2 factor (E2F)-regulated gene expression.
  • Inquiry Price
8-10 weeks
Size
QTY
cdk4/6-in-14
T729512699091-15-9
CDK4 6-IN-14 is a potent, highly selective inhibitor of Cyclin-Dependent Kinases 4 and 6 (CDK4 6), with inhibition concentrations (IC50s) of 10 nM and 16 nM, respectively. It shows over 60-fold selectivity for CDK4 6 compared to CDKs 1, 2, 7, and 9, and exhibits significant selectivity against 205 other kinases.
  • Inquiry Price
6-8 weeks
Size
QTY
CDK4/6-IN-11
T743702139329-47-6
CDK4 6-IN-11 is a potent PROTAC CDK4 6 degrader.
  • Inquiry Price
Size
QTY
CDK4/6-IN-17
T791122035069-96-4
CDK4 6-IN-17 (compound 12) is an orally bioavailable inhibitor of CDK4 6, exhibiting potent activity with IC50 values between 10-100 nM in BE(2) cells, and has demonstrated efficacy in inhibiting tumor growth in the COLO205 xenograft model [1].
  • Inquiry Price
8-10 weeks
Size
QTY
CDK4/6-IN-21
T888972102887-41-0
CDK4 6-IN-21 (compound I-52) is a CDK4 6 inhibitor with IC50 values of 3.88 nM for CDK4 and 3.31 nM for CDK6, exhibiting antitumor activity.
  • Inquiry Price
10-14 weeks
Size
QTY
CDK4/6-IN-21 maleate
T890122765997-88-2
CDK4 6-IN-21 maleate (compound I-52) is a potent inhibitor of CDK4 and CDK6, with IC50 values of 3.88 nM and 3.31 nM, respectively. This compound exhibits antitumor activity.
  • Inquiry Price
10-14 weeks
Size
QTY
CDK4/6-IN-22
T895023036014-62-4
CDK4 6-IN-22 (Compound 1-A) is a dual inhibitor of CDK4 and CDK6.
  • Inquiry Price
10-14 weeks
Size
QTY
CDK4/6-IN-13
T626051908454-70-5
Compounds 10B and 10C, functioning as cdk4 6 inhibitors, demonstrated low nanomolar activity, optimal antiproliferative effects, excellent metabolic properties, and acceptable pharmacokinetics targeting cdk4 6.
  • Inquiry Price
10-14 weeks
Size
QTY
CDK4/6-IN-19
T880763033950-86-3
CDK4 6-IN-19 (Compound II-7) serves as an inhibitor of CDK4 and CDK6, exhibiting IC 50 values of 0.2 nM and 5.0 nM, respectively. Additionally, it suppresses cell proliferation and is applicable in cancer research.
  • Inquiry Price
10-14 weeks
Size
QTY
CDK4/6-IN-20
T881193033950-84-1
  • Inquiry Price
10-14 weeks
Size
QTY
Abemaciclib metabolite M20
CDK4 6-IN-4, LSN3106726
T107382138499-06-4In house
Abemaciclib metabolite M20 (CDK4 6-IN-4) is an active metabolite of Abemaciclib. Abemaciclib metabolite M20 is a selective CDK4 6 inhibitor and can be used for researches on the treatment of cancer.
  • Inquiry Price
6-8 weeks
Size
QTY
GP-82996
CINK4, Cdk4 6 Inhibitor IV
T21720359886-84-3In house
GP-82996 (CINK4) is a pharmacological inhibitor specifically targeting CDK4 6, exhibiting IC50 values of 1.5 μM for CDK4 cyclin D1, 5.6 μM for CDK6 cyclin D1, and 25 μM for Cdk5 p35. It effectively induces apoptosis in U2OS cancer cells, positioning it as a potential investigational tool in cancer research [1] [2].
  • Inquiry Price
7-10 days
Size
QTY
lerociclib
G1T-38, G1T38, G1T 38
T113451628256-23-4
Lerociclib (G1T38) is a selective and highly potent CDK4 6 inhibitor with anticancer and antitumor activity, inhibits CDK4 CyclinD1 and CDK6 CyclinD3, and inhibits tumor growth in an animal model of endocrine-resistant breast cancer. Due to the poor solubility, for animal studies, the salt form T11345L is recommended.
  • Inquiry Price
8-10 weeks
Size
QTY